The earnings call reveals Amgen's resilience amidst challenges like declining EPOGEN sales and increasing competition. The company's performance in international markets and its confident tone regarding future prospects are positive indicators. However, the focus on managing expenses and the potential impact of upcoming biosimilar competition mildly concerns investors. Overall, the stock is likely to Experience a mild positive bump in the short term. 

1